DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report sent to investors on Monday. The firm issued a hold rating on the stock.

Separately, JMP Securities restated a “market outperform” rating and set a $10.00 price target on shares of DBV Technologies in a research note on Friday, January 10th.

DBV Technologies Stock Performance

DBV Technologies stock opened at $7.07 on Monday. DBV Technologies has a one year low of $2.20 and a one year high of $8.50. The stock has a market cap of $145.42 million, a PE ratio of -1.57 and a beta of -0.08. The stock has a 50-day moving average of $4.99 and a two-hundred day moving average of $4.09.

Institutional Trading of DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC purchased a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.